
Fabio Girardi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1002618/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000–2014 in 59 countries (CONCORD-3). British Journal of Dermatology, 2022, 187, 364-380.	1.5	17
2	Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries. The Lancet Child and Adolescent Health, 2022, 6, 409-431.	5.6	24
3	The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3). Neuro-Oncology, 2021, 23, 1765-1776.	1.2	21
4	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. European Journal of Cancer, 2021, 153, 133-141.	2.8	20
5	Global Trends in Survival From Astrocytic Tumors in Adolescents and Young Adults: A Systematic Review. JNCI Cancer Spectrum, 2020, 4, pkaa049.	2.9	5
6	Trends in short-term survival from distant-stage cutaneous melanoma in the United States, 2001-2013 (CONCORD-3). JNCI Cancer Spectrum, 2020, 4, pkaa078.	2.9	8
7	Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncology, The, 2020, 21, e185-e224.	10.7	177
8	Worldwide Trends in Survival From Common Childhood Brain Tumors: A Systematic Review. Journal of Global Oncology, 2019, 5, 1-25.	0.5	37
9	Global childhood cancer survival estimates and priority-setting: a simulation-based analysis. Lancet Oncology, The, 2019, 20, 972-983.	10.7	136
10	Colorectal cancer incidence among young adults in England: Trends by anatomical sub-site and deprivation. PLoS ONE, 2019, 14, e0225547.	2.5	28
11	Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. Genetics in Medicine, 2018, 20, 1575-1582.	2.4	15
12	Risk of breast or ovarian cancer in family members who do not carry the BRCA1 or BRCA2 family mutation: Findings from the EMBRACE study Journal of Clinical Oncology, 2017, 35, 1558-1558.	1.6	0
13	Cardiovascular Safety of VEGF-Targeting Therapies: Current Evidence and Handling Strategies. Oncologist, 2010, 15, 683-694.	3.7	43
14	Bevacizumab in brain tumors: ready for primetime?. Future Oncology, 2009, 5, 1183-1184.	2.4	5